EC Number |
Inhibitors |
Structure |
---|
1.14.14.127 | 1-(2-methylpropyl)-5-[4-([4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzyl]oxy)phenyl]-1H-imidazole |
bifunctional compound, inhibits juvenile hormone III synthesis by intact glands as well as methyl farnesoate epoxidation by gland homogenates. Using the compound, a radiolabeled and photoactivatable diazirine or benzophenone group can be introduced to label the hydrophobic substrate binding site of the enzyme |
|
1.14.14.127 | 5-(2-(benzyloxy)phenyl)-1-(3,7-dimethyloct-6-en-1-yl)-1H-imidazole |
- |
|
1.14.14.127 | 5-(3-[[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy]phenyl)-1-(2-methylpropyl)-1H-imidazole |
- |
|
1.14.14.127 | 5-[3-(benzyloxy)phenyl]-1-(2-methylpropyl)-1H-imidazole |
- |
|
1.14.14.127 | carbon monoxide/oxygen atmosphere |
half-maximal inhibition at a CO/O ratio of 4.0. Inhibition is reversed by white-light irradiation |
|
1.14.14.127 | cytochrome c |
inhibition by oxidized cytochrome c, 20 microM, 52.4% residual activity |
|
1.14.14.127 | methyl (2E,6E)-3,7-dimethyl-8-(3,4-methylenedioxyphenoxy)-octadienoate |
inhibits juvenile hormone biosynthesis in vitro by spontaneously active glands, presumably by direct inhibition of the epoxidase, and also inhibits the production of total methyl ester |
|
1.14.14.127 | more |
inhibition 1,5-disubstituted imidazoles |
|
1.14.14.127 | NADP+ |
2 mM, 57.2% residual activity |
|
1.14.14.127 | [4-([4-[1-(2-methylpropyl)-1H-imidazol-5-yl]phenoxy]methyl)phenyl](phenyl)methanone |
bifunctional compound, inhibits juvenile hormone III synthesis by intact glands as well as methyl farnesoate epoxidation by gland homogenates. Using the compound, a radiolabeled and photoactivatable diazirine or benzophenone group can be introduced to label the hydrophobic substrate binding site of the enzyme |
|